5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.62▼ | 4.62▼ | 4.61▼ | 4.53▲ | 4.49▲ |
MA10 | 4.62▼ | 4.61▲ | 4.61▼ | 4.51▲ | 4.44▲ |
MA20 | 4.62▼ | 4.61▲ | 4.57▲ | 4.48▲ | 4.34▲ |
MA50 | 4.60▲ | 4.55▲ | 4.53▲ | 4.42▲ | 4.82▼ |
MA100 | 4.57▲ | 4.52▲ | 4.46▲ | 4.40▲ | 4.75▼ |
MA200 | 4.52▲ | 4.46▲ | 4.50▲ | 4.58▲ | 6.75▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.004▼ | -0.001▼ | 0.001▲ | 0.015▲ | 0.042▲ |
RSI | 48.122▼ | 54.188▲ | 56.219▲ | 56.931▲ | 50.876▲ |
STOCH | 52.778 | 84.405▲ | 83.453▲ | 70.528 | 62.242 |
WILL %R | -66.667 | -15.789▲ | -17.073▲ | -10.870▲ | -46.622 |
CCI | -135.484▼ | 36.515 | 40.580 | 108.930▲ | 19.437 |
MA | $ACHV Price Crossed Above MA(200) | Set Alert |
Wednesday, April 17, 2024 07:59 PM
Fintel reports that on April 17, 2024, JonesTrading initiated coverage of Achieve Life Sciences ( NasdaqCM:ACHV) with a Buy recommendation.
|
Wednesday, April 17, 2024 02:41 PM
Jones Research started coverage of Achieve Life Sciences (ACHV) with a buy rating, citing the company’s market opportunity for tobacco cessation products. Read more here.
|
Thursday, April 04, 2024 04:30 AM
Achieve Life Sciences (NASDAQ:ACHV) went public via a shell company in 2017 to commercialize the smoking cessation drug Cytisinicline. Cytisinicline is derived from a plant-based compound and has ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 4.57 | 4.64 | 4.48 | 4.61 | 57,002 |
25/04/24 | 4.47 | 4.66 | 4.43 | 4.575 | 56,633 |
24/04/24 | 4.52 | 4.54 | 4.445 | 4.54 | 31,736 |
23/04/24 | 4.42 | 4.5899 | 4.35 | 4.50 | 51,613 |
22/04/24 | 4.57 | 4.58 | 4.35 | 4.41 | 82,081 |
19/04/24 | 4.55 | 4.6192 | 4.43 | 4.51 | 35,387 |
18/04/24 | 4.59 | 4.65 | 4.39 | 4.57 | 77,779 |
17/04/24 | 4.53 | 4.59 | 4.45 | 4.57 | 53,175 |
16/04/24 | 4.50 | 4.5806 | 4.37 | 4.38 | 63,224 |
15/04/24 | 4.34 | 4.48 | 4.20 | 4.45 | 114,653 |
|
|
||||
|
|
||||
|
|